Generali Asset Management SPA SGR Has $7.34 Million Position in Pfizer Inc. $PFE

Key Points

• Generali Asset Management SPA SGR increased its stake in Pfizer by 18.3%, acquiring a total of 302,739 shares valued at approximately $7.34 million.
• Several hedge funds adjusted their holdings in Pfizer, with institutions collectively owning 68.36% of the company's stock.
• Pfizer announced a quarterly dividend of $0.43, translating to a 7.1% dividend yield, with the ex-dividend date set for November 7th.

Generali Asset Management SPA SGR lifted its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 18.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 302,739 shares of the biopharmaceutical company's stock after purchasing an additional 46,785 shares during the quarter. Generali Asset Management SPA SGR's holdings in Pfizer were worth $7,338,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of PFE. Bessemer Group Inc. increased its position in Pfizer by 11.1% during the first quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company's stock worth $3,358,000 after buying an additional 13,228 shares during the last quarter. Capital Advisors Inc. OK grew its position in shares of Pfizer by 1.2% in the first quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company's stock valued at $35,817,000 after purchasing an additional 17,032 shares during the last quarter. CHURCHILL MANAGEMENT Corp acquired a new stake in shares of Pfizer in the first quarter valued at about $8,283,000. Westbourne Investments Inc. acquired a new stake in shares of Pfizer in the first quarter valued at about $2,411,000. Finally, Bourne Lent Asset Management Inc. grew its position in shares of Pfizer by 90.8% in the second quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company's stock valued at $927,000 after purchasing an additional 18,200 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Pfizer in a report on Wednesday, October 8th. Bank of America raised their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock a "neutral" rating in a research note on Friday, October 3rd. UBS Group restated a "neutral" rating and issued a $28.00 price objective on shares of Pfizer in a research note on Wednesday, October 1st. Citigroup raised their price target on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Finally, Morgan Stanley decreased their price target on shares of Pfizer from $33.00 to $32.00 and set an "equal weight" rating on the stock in a research report on Friday, October 10th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $28.35.

Pfizer Stock Down 0.5%

PFE opened at $24.39 on Thursday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The firm's fifty day moving average price is $24.89 and its two-hundred day moving average price is $24.13. The company has a market capitalization of $138.69 billion, a P/E ratio of 12.98, a P/E/G ratio of 0.81 and a beta of 0.55. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $29.82.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company's quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the business earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.1%. The ex-dividend date is Friday, November 7th. Pfizer's payout ratio is currently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.